Endo to buy Par Pharma for $8B to bulk up in injectables

Endo ($ENDP) is acquiring Par Pharmaceutical for $8 billion. It adds about 100 products from Par, such as generic injectables worth $1.3 billion in 2014 sales. Injectables are tougher to manufacture than pills, which means the competition is lower, garnering higher profitability. "This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A," Endo CEO Rajiv De Silva said. More